Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Marker Therapeutics Inc (MRKR)

Marker Therapeutics Inc (MRKR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Marker Therapeutics Inc 9350 Kirby Drive Suite 300 Houston TX 77054 USA

www.markertherapeutics.com P: 713-400-6400

Description:

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of innovative peptide and nucleic acid-based immunotherapeutic vaccines for the treatment and eradication of cancer, including metastatic cancer. The company's product pipeline consists of MultiTAA T Cell Therapy, TPIV200 and TPIV100/110 which are in clinical stage. Marker Therapeutics Inc., formerly known as TapImmune Inc., is based in FL, United States.

Key Statistics

Overview:

Market Capitalization, $K 37,615
Enterprise Value, $K 22,505
Shares Outstanding, K 8,913
Annual Sales, $ 3,310 K
Annual Net Income, $ -8,240 K
Last Quarter Sales, $ 260 K
Last Quarter Net Income, $ -2,980 K
EBIT, $ -16,230 K
EBITDA, $ -12,550 K
60-Month Beta 1.54
% of Insider Shareholders 24.10%
% of Institutional Shareholders 22.39%
Float, K 6,765
% Float 75.90%
Short Volume Ratio 0.13

Growth:

1-Year Return 193.19%
3-Year Return -82.04%
5-Year Return -92.97%
5-Year Revenue Growth 1,476.19%
5-Year Earnings Growth 90.48%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.34 on 11/09/23
Latest Earnings Date 05/21/24
Earnings Per Share ttm -1.38
EPS Growth vs. Prev Qtr 27.66%
EPS Growth vs. Prev Year 57.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 01/27/23

MRKR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -248.94%
Debt/Equity 0.00
Price/Sales 11.31
Price/Cash Flow N/A
Price/Book 2.66
Book Value/Share 1.90
Interest Coverage -0.88
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar